Provention Bio Inc (PRVB)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

P.O. BOX 666 OLDWICK, NJ 08858

Provention Bio, Inc. operates as a biopharmaceutical company. The Company focuses on development of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Provention Bio serves patients in the State of New Jersey.

Data as of 2020-08-01
Market Cap582.467 Million Shares Outstanding56.06 Million Avg 30-day Volume1.17 Million
P/E Ratio Dividend Yield EPS-1.03
Price/Sales Price cash flow ratio Price free cash flow ratio-21.3
Book Value1.27 Price to Tangible Book8.34 Alpha0.07
Short Interest Ratio % Short Interest to Float R-squared0.223781
BETA3.61489 52-week High/Low18.5 / 4.72 Stddev0.446268
View SEC Filings from PRVB instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 1 0 (0.0%)
13F Filers holding this stock: 65 22 (1.44%)
Aggregate 13F shares on 03/31/2020: 10.457 Million 6.239 Million
Aggregate 13F shares on 12/31/2019: 8.797 Million 5.414 Million
Percent change: 18.87% 15.24%
Funds creating new positions: 22 8
Funds Adding to an existing position: 20 6
Funds closing out their position: 16 7
Funds reducing their position: 18 7
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding PRVB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PRVB BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

2 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KING-JONES HEIDY CHIEF LEGAL OFFICER

  • Officer
0 2020-08-03 2

DIGIANDOMENICO ANTHONY

  • Director
382,012 2020-07-21 6

DRECHSLER ANDREW T CHIEF FINANCIAL OFFICER

  • Officer
0 2020-07-15 1

LEON FRANCISCO CHIEF SCIENTIFIC OFFICER

  • Officer
0 2020-07-15 6

PALMER ASHLEIGH PRESIDENT AND CEO

  • Officer
  • Director
0 2020-07-15 4

RAMOS ELEANOR CHIEF MEDICAL OFFICER

  • Officer
0 2020-07-15 2

PISANO WAYNE

  • Director
0 2020-07-15 1

CATLIN AVERY W

  • Director
0 2020-07-15 1

BLUESTONE JEFFREY

  • Director
0 2020-07-15 2

DOHERTY SEAN M

  • Director
0 2020-07-15 3

HOITT JASON CHIEF COMMERCIAL OFFICER

  • Officer
0 2020-07-15 4

WYSENSKI NANCY

  • Director
0 2020-07-15 3

JOHNSON & JOHNSON

JOHNSON & JOHNSON INNOVATION - JJDC, INC.

  • 10% Owner
3,670,516 2020-06-30 0

GRAY CAMERON

  • Director
0 2020-01-02 0

CATLIN AVERY W

CATLIN AVERY W

  • Director
0 2018-09-05 1

MDB CAPITAL GROUP LLC

  • 10% Owner
No longer subject to file 2018-07-19 0

VACTECH OY

  • 10% Owner
No longer subject to file 2018-07-19 0

APPEL PETER A

  • 10% Owner
No longer subject to file 2018-07-19 0

MACROGENICS INC

  • 10% Owner
0 2018-07-03 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

KING-JONES HEIDY - Officer CHIEF LEGAL OFFICER

2020-08-03 A 300,000 d 300,000 0.00 direct

CATLIN AVERY W - Director

2020-07-15 A 22,200 a 22,200 0.00 direct

WYSENSKI NANCY - Director

2020-07-15 A 22,200 a 22,200 0.00 direct

DOHERTY SEAN M - Director

2020-07-15 A 22,200 a 22,200 0.00 direct

PALMER ASHLEIGH - Director - Officer PRESIDENT AND CEO

2020-07-15 A 137,750 a 137,750 0.00 direct

LEON FRANCISCO - Officer CHIEF SCIENTIFIC OFFICER

2020-07-15 A 137,750 a 137,750 0.00 direct

RAMOS ELEANOR - Officer CHIEF MEDICAL OFFICER

2020-07-15 A 137,750 a 137,750 0.00 direct

PISANO WAYNE - Director

2020-07-15 A 22,200 a 22,200 0.00 direct

DRECHSLER ANDREW T - Officer CHIEF FINANCIAL OFFICER

2020-07-15 A 137,750 a 137,750 0.00 direct

BLUESTONE JEFFREY - Director

2020-07-15 A 22,200 a 22,200 0.00 direct

HOITT JASON - Officer CHIEF COMMERCIAL OFFICER

2020-07-15 A 137,750 a 137,750 0.00 direct

LEON FRANCISCO - Officer CHIEF SCIENTIFIC OFFICER

2020-06-24 P 2,000 $15.43 a 2,565,450 2,565,450.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments